- Home
- EVRG vs NTRA Comparison
EVRG vs NTRA Comparison
Compare EVRG & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVRG
- NTRA
- Stock Information
- Founded
- EVRG 2017
- NTRA 2003
- Country
- EVRG United States
- NTRA United States
- Employees
- EVRG N/A
- NTRA N/A
- Industry
- EVRG Power Generation
- NTRA Medical Specialities
- Sector
- EVRG Utilities
- NTRA Health Care
- Exchange
- EVRG Nasdaq
- NTRA Nasdaq
- Market Cap
- EVRG 14.2B
- NTRA 15.3B
- IPO Year
- EVRG N/A
- NTRA 2015
- Fundamental
- Price
- EVRG $63.76
- NTRA $146.06
- Analyst Decision
- EVRG Buy
- NTRA Strong Buy
- Analyst Count
- EVRG 7
- NTRA 17
- Target Price
- EVRG $62.57
- NTRA $141.88
- AVG Volume (30 Days)
- EVRG 1.9M
- NTRA 1.3M
- Earning Date
- EVRG 11-07-2024
- NTRA 11-12-2024
- Dividend Yield
- EVRG 4.03%
- NTRA N/A
- EPS Growth
- EVRG 25.01
- NTRA N/A
- EPS
- EVRG 3.70
- NTRA N/A
- Revenue
- EVRG $5,777,800,000.00
- NTRA $1,531,955,000.00
- Revenue This Year
- EVRG $7.40
- NTRA $42.99
- Revenue Next Year
- EVRG $2.28
- NTRA $13.31
- P/E Ratio
- EVRG $17.23
- NTRA N/A
- Revenue Growth
- EVRG 3.18
- NTRA 54.94
- 52 Week Low
- EVRG $48.04
- NTRA $53.06
- 52 Week High
- EVRG $64.07
- NTRA $167.79
- Technical
- Relative Strength Index (RSI)
- EVRG 65.62
- NTRA 62.68
- Support Level
- EVRG $62.71
- NTRA $133.01
- Resistance Level
- EVRG $64.07
- NTRA $167.79
- Average True Range (ATR)
- EVRG 1.07
- NTRA 6.12
- MACD
- EVRG 0.30
- NTRA 2.93
- Stochastic Oscillator
- EVRG 93.60
- NTRA 55.20
About EVRG Evergy Inc.
Evergy is a regulated electric utility serving eastern Kansas and western Missouri. Major operating subsidiaries include Evergy Metro, Evergy Kansas Central, Evergy Missouri West, and Evergy Transmission Co. The utility has a combined rate base of approximately $20 billion, about half in Kansas and the rest split between Missouri and federal jurisdiction. Evergy is one of the largest wind energy suppliers in the US.
About NTRA Natera Inc.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.